<DOC>
	<DOC>NCT00522015</DOC>
	<brief_summary>to show that 1. patients improve and stabilize after 12 -24 week treatment with rivastigmine in memory function 2. use of rivastigmine has a positive effect on apathy in PSP patients 3. therapy with rivastigmine has a no positive benefit on speech and overall results of the MMST 4. changes in motor activity are associated with changes in language and overall results of the in MMST</brief_summary>
	<brief_title>Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Supranuclear Palsy, Progressive</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>diagnosis of PSP willingness to participate in the study informed consent ability to speak no further CNS diseases written informed consent stable state of health ability to give informed consent, will checked by an independent physician alcohol abuses acute psychosis pregnancy or lactation known previous drug reaction or hypersensitivity of rivastigmine or other carbamate derivatives liver failure known sick sinus syndrome or excitation disturbance known ulcus ventriculi or duodenal ulcer known asthma or COPD seizures renal failure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>PSP</keyword>
	<keyword>dementia</keyword>
	<keyword>neuropsychology</keyword>
	<keyword>treatment</keyword>
</DOC>